Showing 721-730 of 1846 results for "".
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- JAK Inhibitor Combo Shows Promise in Alopecia Areatahttps://practicaldermatology.com/news/jak-inhibitor-combo-shows-promise-in-alopecia-areata/2461002/Ritlecitinib and brepocitinib show significant improvement in scalp alopecia areata biomarkers, according to a phase 2a clinical trial published inthe Journal of Allergy and Clinical Immunology. Rese
- Janssen Launches National Biologic Coordinators Dayhttps://practicaldermatology.com/news/janssen-launches-national-biologic-coordinators-day/2460973/It’s National Biologic Coordinators Day. Janssen Pharmaceuticals has launched the first national awareness day on November 1 to recognize Biologic Coordinators’ daily commitment to patient care. Even as the use of biologic therapies continues to exp
- EWG: UVA Protection of Most Sunscreens Just 25 Percent of Touted SPFhttps://practicaldermatology.com/news/ewg-most-sunscreens-comprise-just-25-percent-of-touted-spf/2460962/Many sunscreens offer just a quarter of their stated SPF protection against ultraviolet A rays, a new Environmental Working Group (EWG)
- Reistone’s Topical JAK Inhibitor Performs Well in Mild to Moderate ADhttps://practicaldermatology.com/news/reistones-topical-jak-inhibitor-performs-well-in-mild-to-moderate-ad/2460951/Reistone Biopharma’s SHR0302 ointment performed well in a Phase 2 study of patients with mild-to-moderate atopic dermatitis (AD), the company reports. SHR0302 ointment, a topical, selective JAK1 inhibitor, met key primary and secondary endpoints, demonstrating significant improvem
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- PsO Improves Among Patients Who Switch to Janssen's Tremfya from Adalimumabhttps://practicaldermatology.com/news/pso-improves-among-patients-who-switch-to-janssens-tremfya-from-adalimumab/2460940/A total of 19 abstracts at the European Academy of Dermatology Venereology 30th Anniversary Congress will present data for Janssen’s Tremfya (guselkumab), including data showing an improvement in PASI response for psoriasis (PsO
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- Accure Acne, Inc. Appoints Jeffrey O'Donnell, Sr. to the Boardhttps://practicaldermatology.com/news/accure-acne-inc-announces-the-appointment-of-jeffrey-odonnell-sr-to-the-board/2460918/Jeffrey O'Donnell, Sr. has joined Accure Acne's Board of Directors. Along with Chairman and Founder Christopher Carlton and Founder Ed Barbera, Mr. O'Donnell provides strategic guidance for Accure's i
- DermWire Special Report: JAK Inhibitors in Dermatologyhttps://practicaldermatology.com/news/dermwire-special-report-jak-inhibitors-in-dermatology/2460916/By Denise Mann, Editor at Large Lots of hope is pinned on Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis (AD), alopecia areata, vitiligo, plus other skin diseases, and the pipeline is full. Will the recent FDA decision to expand the boxed w